Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult.
| Autor: | Kenyon CM; University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, Utah., Kelly BG; Department of Dermatology, University of Utah, Salt Lake City, Utah., Bowen AR; Department of Dermatology, University of Utah, Salt Lake City, Utah., Gumbleton M; Division of Oncology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.; Huntsman Cancer Institute, Salt Lake City, Utah., Deacon DC; Department of Dermatology, University of Utah, Salt Lake City, Utah.; Huntsman Cancer Institute, Salt Lake City, Utah. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JAAD case reports [JAAD Case Rep] 2024 Jun 15; Vol. 52, pp. 34-37. Date of Electronic Publication: 2024 Jun 15 (Print Publication: 2024). |
| DOI: | 10.1016/j.jdcr.2024.05.038 |
| Abstrakt: | Competing Interests: Dr Gumbleton reports patents licensed to Alterna Therapeutics and honoraria from MJH Lifesciences and OMNI Health Media; all outside the scope of this publication. Drs Kelly, Bowen, Deacon, and Ms Kenyon have no conflicts of interest to declare. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|